Security key
413197104
Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
CUSIP: 413197104
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 49,890,282
- Total 13F value
- $1,866,237,475
- Share change
- +2,428,331
- Put/Call ratio
- 68%
- SEC-reported price per share
- $37.42
- Number of holders
- 323
- Value change
- +$93,866,889
- Number of buys
- 168
- Number of sells
- 139
- Shares outstanding
- 57,644,670
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
323
Top holders
10
HRMY full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Harmony Biosciences Holdings, Inc. SEC filings
Harmony Biosciences Holdings, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 413197104
Recent filing periods:
Ownership snapshot
Top reported holders of HRMY - Harmony Biosciences Holdings, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Marshman Fund Trust II
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
31 Dec 2025
3/4/5
13D/G
13F
Lead comparable stake: 11%
13D/G row: Marshman Fund Trust II
Showing 1-6 of 15 holder rows.
Quick read
Marshman Fund Trust II leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Marshman Fund Trust II's linked filing trail.
Comparable ownership
Top 5
Marshman Fund Trust II
11%
BlackRock, Inc.
10%
FMR LLC
5.4%
Valor IV Pharma Holdings, LLC
0.04%
VANGUARD GROUP INC
8.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Marshman Fund Trust II |
3/4/5
13D/G
10%+ Owner
|
11%
from 13D/G
|
$183,364,064
6,051,120 shares
|
— | 01 Nov 2024 |
| BlackRock, Inc. |
13F
13D/G
Company
|
10%
from 13D/G
|
$190,878,961
6,925,942 shares
|
— | 30 Sep 2025 |
| FMR LLC |
13D/G
13F
Company
|
5.4%
|
$116,481,431
3,112,812 shares
|
-$27,472,267 | 31 Dec 2025 |
| Valor IV Pharma Holdings, LLC |
3/4/5
10%+ Owner
|
0.04%
|
$834,732
23,714 shares
|
— | 28 Aug 2025 |
| VANGUARD GROUP INC |
13F
Company
|
8.8%
|
$140,478,171
5,097,176 shares
|
— | 30 Sep 2025 |
| DIMENSIONAL FUND ADVISORS LP |
13F
Company
|
2.9%
|
$46,620,388
1,691,581 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
323
Shares
49,890,282
Rows available
323
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
292
Q4 2025 holders
323
Holder diff
31
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend